Needham Maintains Buy Rating on Boston Scientific, Keeps $48 Target
Needham maintained its Buy rating on Boston Scientific and a $48.00 price target. The target implies 6.5% upside from the Oct. 27 close of $45.06.
Related stories
ICE Reports Fiscal Q3 Profit of 33.11亿美元, Up 34.38%
Intercontinental Exchange reported fiscal third-quarter profit attributable to shareholders of 33.11亿美元, up 34.38% year over year, with basic EPS of 5.87美元.
M impact | EQUITY | Oct 30, 2026, 05:50 AM UTC
Indian Markets Open Flat as Tech Sell-Off and Crude Surge Weigh
Indian equities opened flat on Friday, with a technology-stock sell-off and higher crude prices weighing on sentiment; domestic institutional buying provided a cushion.
M impact | EQUITY | Oct 30, 2026, 05:47 AM UTC
MRK Reports Fiscal Q3 Net Loss
MRK reported a fiscal third-quarter net loss attributable to shareholders, down 103.34% year over year.
M impact | EQUITY | Oct 30, 2026, 05:45 AM UTC
MA Reports Fiscal Q3 Profit of 129亿美元, Up 18.24%
MA reported fiscal third-quarter profit attributable to shareholders of 129亿美元, up 18.24% year over year, with basic EPS of 14.61美元.
M impact | EQUITY | Oct 30, 2026, 05:45 AM UTC
MO Reports Fiscal 2026 Q3 Profit, Up 20.05%
MO reported fiscal third-quarter profit attributable to shareholders up 20.05% year over year, and basic EPS.
M impact | EQUITY | Oct 30, 2026, 05:45 AM UTC
LLY Reports Fiscal Q3 Profit Growth of 49.56%
The report states fiscal third-quarter profit attributable to shareholders rose 49.56% year over year and basic EPS was reported.
M impact | EQUITY | Oct 30, 2026, 05:42 AM UTC